Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs ...
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback